International Clinical Trials Day 2017

Comments

Transcription

International Clinical Trials Day 2017
International Clinical Trials Day 2017
Key Messages
Clinical trials are an essential part of a research and development process that continues to
change the outcomes for patients and transform the way we are able to deliver healthcare. Since
the 1990 death rates from cancer have fallen by 21% in the EU5, over 95% of the 15 million
people in Europe living with Hepatitis C can be cured through a course of medicine and HIV, a
death sentence in the 1980s is now a disease that can be managed.
According to the European Medicines Agency (EMA) suggests that some 4,000 trials are
authorised each year across the EEA, a phenomenal effort, in partnership with other global
research partners.
Clinical trials are stringently regulated procedures that prove the safety and efficacy of
treatments. The outcomes of medical research have contributed significantly to the wellbeing and
longevity of Europe’s citizens over many decades.
Clinical Trials are an essential part of research, representing 58.6% of a product’s total
development costs, with a medicine typically in trials for 6-12 years.
Clinical trials are key to providing patients with early access to the latest medical innovations.
Clinical trials offer the European research and clinical community the opportunity to work with
the latest scientific discoveries and innovative medical care.
Clinical Trials contribute significantly to the European knowledge economy, and to achieving the
EU 2020 headline target of 3% of GDP invested in R&D.
Clinical Trials coupled with an increased focus on big data will help us rise to continuing health
challenges, including the increasing prevalence of chronic conditions, increased antimicrobial
resistance, and finding treatments for the over 6000 different rare diseases we know today.
Clinical trials must always respect the highest ethical and scientific standards of patient safety and
data reliability, according to agreed international standards.
Europe has traditionally been strong in life sciences, and the EU2020 strategy recognises the
importance of innovation. The new Clinical Trials Regulation streamlines procedures and gives
Europe a chance to turn recognition into action.
www.efpia.eu
1
www.efpia.eu
2

Similar documents